Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast bringing you the latest insights shaping patient access, regulatory policy, and healthcare innovation. I'm your host, and let's get into today's headlines.
First up, a new survey from hospital intelligence firm Bluesight, conducted with 437 hospital pharmacy professionals in January and February of this year, highlights the operational and regulatory pressures weighing on hospital pharmacy teams heading into the second half of 2026. Drug shortages topped the list of challenges for the seventh consecutive year, cited by 78.3% of respondents. Sixty percent said they are currently managing more than 10 active shortages, and nearly 10% report spending more than 30 hours a week on shortage management alone — with 69.7% still relying primarily on spreadsheets to do it. On the 340B front, 66.7% of pharmacy leaders responsible for 340B management identified a potential transition to a rebate model as their most pressing concern, citing a three-front battle of navigating the stalled rebate pilot, new IRA pricing complexities, and escalating manufacturer pressure demanding claims data while threatening to revoke 340B pricing altogether.
In regulatory news, the FDA issued draft guidance aimed at helping developers bring gene therapies to patients more efficiently. When finalized, the guidance will outline how sponsors can leverage publicly available information and established platform knowledge — including chemistry, manufacturing and controls data, nonclinical study results, and prior clinical information — to streamline regulatory submissions for genome-editing products in human somatic cells. The guidance complements the agency's previously issued Plausible Mechanism Framework and its recently released draft guidance on next-generation sequencing safety assessment, forming a coordinated suite of FDA actions in the cell and gene therapy space. Acting CBER Director Karim Mikhail said the intent is to accelerate innovation without compromising scientific standards — particularly for patients with rare and life-threatening diseases who have few or no other options.
In distribution and market access news, Cencora has entered an agreement with Kite Pharma to support US distribution of its two FDA-approved CAR T-cell therapies, Yescarta and Tecartus. The collaboration is designed to reduce the operational friction that can delay patient access to these autologous therapies. A January 2026 analysis found that 65% of community oncologists reported patients deteriorating before CAR T administration, with payer approval timelines cited as a primary bottleneck. Cencora's role will span order management across sites of care, specialty distribution with cold-chain capabilities, and ongoing access support — freeing authorized treatment centers to focus on patient care as Kite expands its network.
And finally, Novo Nordisk has launched the Wegovy pill — its once-daily oral semaglutide tablet — in the United Arab Emirates (UAE), making it the first market outside the United States to offer the treatment commercially. Novo selected the UAE based on strong local patient demand, healthcare professional readiness, and robust telehealth infrastructure capable of supporting long-term obesity care. The distribution implications are significant: unlike injectable GLP-1s, the oral formulation bypasses cold-chain requirements entirely, allowing it to move through standard distribution channels. Novo has signaled additional “select market” launches are planned for the second half of 2026.
That's it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit pharmaceuticalcommerce.com. Thanks for listening—until next time, stay well and stay informed.
You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.
